Generic placeholder image

Current Cancer Therapy Reviews

Author(s): Idris Kirhan*, Huseyin Taskiran and Ataman Gönel

DOI: 10.2174/1573394717666210223111332

DownloadDownload PDF Flyer Cite As
Effect of Conventional Chemotherapies on Natural Killer Cell Activity

Page: [251 - 254] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Background: The effects of chemotherapeutics agents are considered to influence the immune system and cells due to their myelosuppressive and immunosuppressive functions. Natural killer cells are one of the important components of the innate immune system and have a critical role against tumor cells and infections.

Objective: The study was aimed to demonstrate whether conventional chemotherapies had an effect on Natural Killer (NK) cell activity.

Methods: Forty-nine adjuvant and 19 first-time metastatic chemotherapy-naïve cancer patients were recruited into the study. Blood samples at pre-chemotherapy and post-chemotherapy, at 1st and 4th cycles, were obtained for NK cell activity.

Results: We found no difference between baseline and post-chemotherapy NK cell activity levels. In addition, we found no difference between pre-chemotherapy and post-chemotherapy NK cell activity in both adjuvant and metastatic cancer patients separately.

Conclusion: Conventional chemotherapy seems to have no effect on NK cell activity levels in cancer patients in both metastatic and adjuvant settings.

Keywords: NK cell activity, cancer, pre-chemotherapy, post-chemotherapy, adjuvant, metastasis.

[1]
Wang K, Han Y, Cho WC, Zhu H. The rise of human stem cell-derived natural killer cells for cancer immunotherapy. Expert Opin Biol Ther 2019; 19(2): 141-8.
[http://dx.doi.org/10.1080/14712598.2019.1559293] [PMID: 30583701]
[2]
Ljunggren HG, Kärre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 1990; 11(7): 237-44.
[http://dx.doi.org/10.1016/0167-5699(90)90097-S] [PMID: 2201309]
[3]
Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998; 188(12): 2375-80.
[http://dx.doi.org/10.1084/jem.188.12.2375] [PMID: 9858524]
[4]
Zhu H, Lai YS, Li Y, Blum RH, Kaufman DS. Concise Review: Human pluripotent stem cells to produce cell-based cancer immunotherapy. Stem Cells 2018; 36(2): 134-45.
[http://dx.doi.org/10.1002/stem.2754] [PMID: 29235195]
[5]
Morvan MG, Lanier LL. NK cells and cancer: You can teach innate cells new tricks. Nat Rev Cancer 2016; 16(1): 7-19.
[http://dx.doi.org/10.1038/nrc.2015.5] [PMID: 26694935]
[6]
Langers I, Renoux VM, Thiry M, Delvenne P, Jacobs N. Natural killer cells: Role in local tumor growth and metastasis. Biologics 2012; 6: 73-82.
[http://dx.doi.org/10.2147/btt.S23976] [PMID: 22532775]
[7]
Lee SB, Cha J, Kim IK, et al. A high-throughput assay of NK cell activity in whole blood and its clinical application. Biochem Biophys Res Commun 2014; 445(3): 584-90.
[http://dx.doi.org/10.1016/j.bbrc.2014.02.040] [PMID: 24561245]
[8]
Corado J, Toro F, Rivera H, Bianco NE, Deibis L, De Sanctis JB. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 1997; 109(3): 451-7.
[http://dx.doi.org/10.1046/j.1365-2249.1997.4581355.x] [PMID: 9328121]
[9]
Kottilil S, Chun TW, Moir S, et al. Innate immunity in human immunodeficiency virus infection: Effect of viremia on natural killer cell function. J Infect Dis 2003; 187(7): 1038-45.
[http://dx.doi.org/10.1086/368222] [PMID: 12660917]
[10]
Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases. Blood 2002; 99(8): 2694-702.
[http://dx.doi.org/10.1182/blood.V99.8.2694] [PMID: 11929755]
[11]
Prolo P, Chiappelli F, Angeli A, et al. Physiologic modulation of natural killer cell activity as an index of Alzheimer’s disease progression. Bioinformation 2007; 1(9): 363-6.
[http://dx.doi.org/10.6026/97320630001363] [PMID: 17597922]
[12]
Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356(9244): 1795-9.
[http://dx.doi.org/10.1016/S0140-6736(00)03231-1] [PMID: 11117911]
[13]
Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: A multivariate analysis. Am J Gastroenterol 2001; 96(2): 574-8.
[http://dx.doi.org/10.1111/j.1572-0241.2001.03535.x] [PMID: 11232710]
[14]
Larsen SK, Gao Y, Basse PH. NK cells in the tumor microenvironment. Crit Rev Oncog 2014; 19(1-2): 91-105.
[http://dx.doi.org/10.1615/CritRevOncog.2014011142] [PMID: 24941376]
[15]
Guillerey C. NK Cells in the Tumor Microenvironment. Tumor Microenvironment. Springer 2020; pp. 69-90.
[16]
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-74.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID: 21376230]